Chikungunya Vaccine Companies
vaccine development involves collaboration between research institutions, pharmaceutical companies, and sometimes government agencies. Various companies and organizations may be involved in Chikungunya vaccine research.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Latest Chikungunya Vaccine Companies Updates:
Valneva: Their chikungunya vaccine, VLA1553 (Ixchiq®), received FDA approval in November 2023 and EMA approval in December 2023, marking a major milestone for the market.
Valneva is actively launching the vaccine in the US and targeting further approvals in other countries.
Bavarian Nordic: Their chikungunya vaccine candidate, PXVX0317, is undergoing Phase 3 clinical trials and is expected to seek regulatory approval in 2024. This could provide another option for the market and potentially drive competition.
Bharat Biotech: Partnered with the International Vaccine Institute to develop their chikungunya vaccine candidate, BBV87. This vaccine is currently in Phase 3 clinical trials and could be another contender for market entry.
Defender Pharmaceuticals: Collaborated with the US Army Medical Research Institute of Infectious Diseases to develop their chikungunya vaccine candidate, TSIGSD-218. This vaccine is in Phase 2 clinical trials and may contribute to further research and development.
List of Chikungunya Vaccine Key companies in the market:
-
Allergan Inc (Ireland)
-
Merz Pharma (Germany)
-
Ipsen (France)
-
Valeant Pharmaceuticals (Canada)
-
Galderma (Switzerland)
-
Integra Lifesciences (Us)
-
Tei Biosciences
-
Fibrogen (Finland)
Chikungunya Vaccine Market Highlights:
Chikungunya Vaccine Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
